Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic Ductal Adenocarcinoma: A Case Report and Literature Review
Journal of Gastrointestinal Cancer · 2025
DOI: 10.1007/s12029-025-01237-5 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Gastrointestinal Cancer, 2025. Verfasst von Kevin Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Melbourne School of Medicine, Melbourne, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Melbourne.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis. While immunotherapy has shown limited efficacy in most PDAC cases due to an immunosuppressive tumour microenvironment, tumours with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) status exhibit increased responsiveness to immune checkpoint inhibitors. Case Presentation We report the case of a 45-year-old woman with Lynch syndrome who was diagnosed with MSI-H/dMMR PDAC during routine surveillance. Given the borderline resectable nature of her tumour and previous chemotherapy-related neurotoxicity, she was treated with neoadjuvant pembrolizumab instead of conventional chemotherapy. Following four cycles of pembrolizumab, imaging revealed a marked metabolic response, allowing for successful R0 pancreatoduodenectomy. Postoperative histology confirmed a significant reduction in tumour size, and immunohistochemical analysis demonstrated increased CD8 + T cell infiltration, supporting an enhanced anti-tumour immune response. The patient continues adjuvant pembrolizumab therapy without complications.
Conclusion
This case highlights the potential role of neoadjuvant pembrolizumab in MSI-H/dMMR PDAC, demonstrating successful tumour downstaging and facilitating surgical resection. Our findings support further investigation into the integration of immunotherapy as a neoadjuvant strategy for select PDAC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Melbourne School of Medicine, Melbourne, Australia.
- Prometheus Research Collaborative, Department of Surgery, Austin Precinct, The University of Melbourne, Austin Health, Melbourne, Australia.
- TissuPath, Mount Waverley, Australia.
- , Radiology Victoria, Melbourne, Australia.
- Australian Clinical Labs, Clayton, Australia.
- Department of Surgery, The University of Melbourne, Austin Health, Melbourne, Australia. prasad.cooray@icloud.com.
Förderung
- University of Melbourne
Zitieren
APA
Zhao, K., Muralidharan, V., Brown, S., Upton, A., Alshimirti, M., & Cooray, P. D. (2025). Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic Ductal Adenocarcinoma: A Case Report and Literature Review. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-025-01237-5
Vancouver
Zhao K, Muralidharan V, Brown S, Upton A, Alshimirti M, Cooray PD. Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic Ductal Adenocarcinoma: A Case Report and Literature Review. Journal of Gastrointestinal Cancer. 2025. doi:10.1007/s12029-025-01237-5
BibTeX
@article{Zhao2025,
author = {Zhao, Kevin and Muralidharan, Vijayaragavan and Brown, Shaun and Upton, Anthony and Alshimirti, Moammar and Cooray, Prasad D},
title = {Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic Ductal Adenocarcinoma: A Case Report and Literature Review},
journal = {Journal of Gastrointestinal Cancer},
year = {2025},
doi = {10.1007/s12029-025-01237-5}
}
EUVIMED